Amgen
Amgen Inc., a leading biotechnology company headquartered in the United States, has been at the forefront of innovation since its founding in 1980. With a strong presence in major operational regions including Europe and Asia, Amgen focuses on developing therapies in areas such as oncology, nephrology, and inflammation. Renowned for its pioneering biologic medicines, Amgen's core products include Enbrel, Neulasta, and Prolia, which are distinguished by their ability to target specific disease pathways effectively. The company has achieved significant milestones, including the introduction of the first recombinant human erythropoietin, Epogen, which transformed the treatment of anaemia. As a prominent player in the biotechnology industry, Amgen continues to excel, holding a strong market position and receiving numerous accolades for its commitment to scientific excellence and patient care.
DitchCarbon Score
How does Amgen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amgen's score of 38 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amgen's reported carbon emissions
In 2024, Amgen reported total carbon emissions of approximately 121,000,000 kg CO2e, comprising about 107,000,000 kg CO2e from Scope 1 and about 14,000,000 kg CO2e from Scope 2 emissions. This marks a significant reduction from 2023, where total emissions were about 165,000,000 kg CO2e, with Scope 1 emissions at approximately 153,000,000 kg CO2e and Scope 2 at about 12,000,000 kg CO2e. Amgen has set ambitious climate commitments, aiming for a 55% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2027, using 2019 as the baseline year. As of 2023, the company achieved 54% of its targeted reductions for these scopes. Additionally, Amgen plans to transition to 100% renewable electricity sourcing by 2027 and maintain this commitment through 2030. Furthermore, they aim for 73% of their suppliers, by spend, to have science-based targets by 2027. These initiatives reflect Amgen's commitment to sustainability and align with industry standards for climate action, contributing to their goal of achieving carbon neutrality for their owned and operated facilities by 2027.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 144,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 290,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amgen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
